

**Learning Activity 4:
Treatment of recurrent CDI**

1. Kelly CP. Can we identify patients at high risk of recurrent *Clostridium difficile* infection? *Clin Microbiol Infect.* 2012;18(Suppl 6):21-27. (<http://www.ncbi.nlm.nih.gov/pubmed/23121551>)
2. Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for *Clostridium difficile* infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). *Infect Control Hosp Epidemiol.* 2010;31:431-455. (<http://www.ncbi.nlm.nih.gov/pubmed/20307191>)
3. Van Nood E, Vriente A, Nieurop M, et al. Duodenal infusion of donor feces for recurrent *Clostridium difficile*. *N Engl J Med.* 2013;368:407-415. (<http://www.ncbi.nlm.nih.gov/pubmed/23323867>)
4. Poutanen SM, Simor AE. *Clostridium difficile*-associated diarrhea in adults. *CMAJ.* 2004;171:51-8. (<http://www.ncbi.nlm.nih.gov/pubmed/15238498>)
5. Eyre DW, Walker AS, Wyllie D, et al. Predictors of first recurrence of *Clostridium difficile* infection: implications for initial management. *Clin Infect Dis.* 2012;55(Suppl 2):S77-87. (<http://www.ncbi.nlm.nih.gov/pubmed/22752869>)
6. Johnson S. Recurrent *Clostridium difficile* infection: causality and therapeutic approaches. *Int J Antimicrob Agents.* 2009;33 Suppl 1:S33-6. (<http://www.ncbi.nlm.nih.gov/pubmed/19303567>)
7. Garey KW, Jiang ZD, Ghantaji S, Tam VH, Arora V, Dupont HL. A common polymorphism in the interleukin-8 gene promoter is associated with an increased risk for recurrent *Clostridium difficile* infection. *Clin Infect Dis.* 2010;51:1406-10. (<http://www.ncbi.nlm.nih.gov/pubmed/21058913>)
8. Bouza E. Consequences of *Clostridium difficile* infection: understanding the healthcare burden. *Clin Microbiol Infect.* 2012;18 Suppl 6:5-12. (<http://www.ncbi.nlm.nih.gov/pubmed/23121549>)
9. Kelly CP, LaMont JT. *Clostridium difficile*--more difficult than ever. *N Engl J Med.* 2008;359:1932-40. (<http://www.ncbi.nlm.nih.gov/pubmed/18971494>)